The World Health Organization (WHO) announced it and its COVAX partners are working with a South African consortium comprising Biovac, Afrigen Biologics and Vaccines, a network of universities and the Africa Centers for Disease Control and Prevention (CDC) to establish its first COVID mRNA vaccine technology transfer hub.
The move follows WHO’s global call for Expression of Interest (EOI) on April 16, 2021 to establish COVID mRNA vaccine technology transfer hubs to scale up production and access to COVID vaccines. Over the coming weeks, the partners will negotiate details with the Government of South Africa and public and private partners inside the country and from around the world.
“This is great news, particularly for Africa, which has the least access to vaccines,” said Dr. Tedros Adhanom Ghebreyesus, WHO Director-General. “COVID-19 has highlighted the importance of local production to address health emergencies, strengthen regional health security and expand sustainable access to health products.”
The announcement follows the recent visit to South Africa by the President of France, Mr. Emmanuel Macron, who said his country was committed to supporting efforts in Africa to scale up local manufacturing capacity of COVID-19 vaccines and other medical solutions.
Technology transfer hubs are training facilities where the technology is established at industrial scale and clinical development performed. Interested manufacturers from low- and middle-income countries can receive training and any necessary licenses to the technology. WHO and partners will bring in the production know-how, quality control and necessary licenses to a single entity to facilitate a broad and rapid technology transfer to multiple recipients. The technology transfer hub will benefit from the Medicines Patent Pool’s (MPP’s) vast experience of intellectual property (IP) management and issuing of IP licenses. MPP is also assisting WHO to negotiate with technical partners and supporting in the governance of the hubs.
Biovac is a bio-pharmaceutical company that is the result of a partnership formed with the South African government in 2003 to establish local vaccine manufacturing capability for the provision of vaccines for national health management and security. Afrigen Biologics and Vaccines is a biotechnology company focuses on product development, bulk adjuvant manufacturing and supply and distribution of key biologicals to address unmet healthcare needs. Biovac will act as developer, Afrigen as manufacturer and a consortium of universities as academic supporters providing mRNA know-how, and Africa CDC for technical and regional support.
The South African consortium benefits from having existing operating facilities that have spare capacity and because it has experience in technology transfers. It is also a global hub that can start training technology recipients immediately.
WHO’s April call for expressions of interest has so far generated 28 offers to either provide technology for mRNA vaccines or to host a technology hub or both. There have been 25 expressions of interest from low- and middle-income country respondents who could receive the technology to produce mRNA vaccines. Over the coming weeks, WHO will continue the rolling evaluation of other proposals and identify additional hubs, as needed, to contribute to health security and equity in all regions. Through the COVAX partnership, WHO will continue its assessment of potential mRNA technology donors and will launch subsequent calls for other technologies, such as viral vectors and proteins, in coming months. WHO is also hosting the Local production forum this week, to identify strategies to expand pharmaceutical manufacturing capacity in low- and middle-income countries for COVID-19 and other priority diseases.
